New study checks safety of advanced breast cancer drug for indian patients
NCT ID NCT06429761
Summary
This study aims to understand the safety of the drug trastuzumab deruxtecan specifically for Indian patients with advanced HER2-positive breast cancer that has spread and cannot be surgically removed. It will involve 100 adult patients who have already received at least one prior anti-HER2 treatment. The main goal is to monitor and record any side effects participants experience while receiving this approved medication.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGBangalore, 560017, India
-
Research Site
RECRUITINGDelhi, 110029, India
-
Research Site
RECRUITINGKochi, 682041, India
-
Research Site
RECRUITINGMumbai, 400012, India
-
Research Site
RECRUITINGPune, 411028, India
-
Research Site
RECRUITINGVaranasi, 221005, India
Conditions
Explore the condition pages connected to this study.